ArticleEuropean journal of preventive cardiology2020
The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk.
Article in European journal of preventive cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06583161 (Emulation of the Moderate Alcohol and Cardiovascular Health Trial), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Emulation of the Moderate Alcohol and Cardiovascular Health Trial (MACH15)
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A burden of proof study on alcohol consumption and ischemic heart disease.Nature communications · 2024Pooled it
- Alcohol consumption in relation to cardiovascular diseases and mortality: a systematic review of Mendelian randomization studies.European journal of epidemiology · 2022Pooled it
- Trial
- Alcohol use disorder: an Australian perspective on screening, diagnosis, treatment and prevention.Internal medicine journal · 2026Review
- The Unfinished Debate on Wine and Other Alcoholic Beverages: Conflicting Evidence, Public Health Messages and the Missing Trial.Nutrients · 2026Review
- Alcohol consumption and incident heart failure in men and women.European journal of heart failure · 2025Article
- Atherogenic Risk and Its Association with Alcohol Consumption, Lifestyle Habits, and Sociodemographic Factors in a Population of Spanish Workers.Life (Basel, Switzerland) · 2025Article
- Characteristics of non-drinking and drinking adults in Taiwan and their implications in alcohol epidemiological studies.PloS one · 2025Article
- Addressing the credibility crisis in Mendelian randomization.BMC medicine · 2024Review
- Article
- Principles of engagement on research and other collaborations between the brewing sector and research entities: the FACT Principles.The British journal of nutrition · 2023Article
- Biomarkers of moderate alcohol intake and alcoholic beverages: a systematic literature review.Genes & nutrition · 2023Review
- Alcohol, Drinking Pattern, and Chronic Disease.Nutrients · 2022Review
- Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context.Current atherosclerosis reports · 2022Review
- Alcohol, cardiovascular disease and industry funding: A co-authorship network analysis of systematic reviews.Social science & medicine (1982) · 2021Article
- Consensus and Controversy in the Debate over the Biphasic Impact of Alcohol Consumption on the Cardiovascular System.Nutrients · 2021Review
- Alcohol use and cardiometabolic risk in the UK Biobank: A Mendelian randomization study.PloS one · 2021Article
Corrections and comments
- Commented on by
Authors and funding
23 authors.
Funding
Abstract
backgroundObservational studies have documented lower risks of coronary heart disease and diabetes among moderate alcohol consumers relative to abstainers, but only a randomized clinical trial can provide conclusive evidence for or against these associations.
aimThe purpose of this study was to describe the rationale and design of the Moderate Alcohol and Cardiovascular Health Trial, aimed to assess the cardiometabolic effects of one alcoholic drink daily over an average of six years among adults 50 years or older.
methodsThis multicenter, parallel-arm randomized trial was designed to compare the effects of one standard serving (∼11-15 g) daily of a preferred alcoholic beverage to abstention. The trial aimed to enroll 7800 people at high risk of cardiovascular disease. The primary composite endpoint comprised time to the first occurrence of non-fatal myocardial infarction, non-fatal ischemic stroke, hospitalized angina, coronary/carotid revascularization, or total mortality. The trial was designed to provide >80% power to detect a 15% reduction in the risk of the primary outcome. Secondary outcomes included diabetes. Adverse effects of special interest included injuries, congestive heart failure, alcohol use disorders, and cancer.
resultsWe describe the design, governance, masking issues, and data handling. In three months of field center activity until termination by the funder, the trial randomized 32 participants, successfully screened another 70, and identified ∼400 additional interested individuals.
conclusionsWe describe a feasible design for a long-term randomized trial of moderate alcohol consumption. Such a study will provide the highest level of evidence for the effects of moderate alcohol consumption on cardiovascular disease and diabetes, and will directly inform clinical and public health guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.